Zhangzhou Pientzehuang Pharmaceutical (SHA:600436) said it enrolled the first participant in the third phase trial of Changji'an capsules for diarrhea-predominant irritable bowel syndrome with liver-qi invading spleen pattern.
The multi-center, double-blind, placebo-controlled study targets an eight-week stool consistency response rate as its primary endpoint, according to a Wednesday filing with the Shanghai bourse.
Shares of the drug company closed 3% lower Wednesday.